ORTHOPEDIATRICS CORP — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
OrthoPediatrics reported Q2 2026 revenue of $70.5M (15% YoY growth) versus $61.1M in Q2 2025. FY2025 revenue was $236.3M (15% growth); company guides FY2026 revenue to $265.0-$269.0M (midpoint $267.0M, ~13% growth). Adjusted EBITDA expected ~$25.0M for FY2026. Gross margin 74% in Q2 2026 vs 72% in Q2 2025. Company is executing product launch roadmap with multiple releases expected through Q4 2027 and expanding OPSB clinic channel in international markets.
Why this rating
Modest growth guidance deceleration (15% to ~13%) offsets steady execution. ~$267M FY2026 guidance is ~74% of company's market cap, routine scale for mature biomedical device company post-IPO.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.